GENFIT Appoints New Chief Medical Officer
GENFIT, a biopharmaceutical company committed to improving lives affected by rare liver diseases, is excited to introduce its new Chief Medical Officer, Dr. Pejvack Motlagh. His appointment marks a significant milestone in GENFIT's strategic evolution towards advancing clinical programs and therapeutic innovations.
Meet Dr. Pejvack Motlagh
Dr. Motlagh joins GENFIT with over two decades of experience in the pharmaceutical and biotechnology sectors. His background encompasses a robust grasp of drug development across various therapeutic areas. As a pivotal member of the Executive Committee, Dr. Motlagh will provide leadership to enhance GENFIT’s clinical development strategy, ensuring a patient-focused approach to innovation.
Strategic Vision for Clinical Development
In his role, Dr. Motlagh will oversee the Clinical Operations and Strategy, Biometrics, and Pharmacovigilance teams. His impressive resume includes the role of CMO at Egle Therapeutics, specializing in therapies for oncology and autoimmune disorders, and Mablink Biosciences, where he focused on next-generation antibody-drug conjugates. His extensive experience in steering drugs from early-phase development to commercialization will guide GENFIT's pipeline advancements.
Dr. Motlagh's Vision
Dr. Motlagh expressed his enthusiasm for joining GENFIT, stating, "I am thrilled to join GENFIT at a pivotal moment, as Acute on-Chronic Liver Failure becomes an increasingly important focus among the liver disease community. Our shared commitment to innovation aligns perfectly with my values. I anticipate collaborating with the exceptional team to press forward on our clinical projects and significantly impact areas with high unmet medical needs." This sentiment underscores GENFIT’s dedication to addressing critical challenges in liver disease research.
Leadership Insights
Pascal Prigent, the CEO of GENFIT, shared his excitement regarding Dr. Motlagh’s appointment, highlighting the depth of expertise that he brings to the company. His proven track record in clinical development across both established pharmaceutical companies and innovative biotech firms is expected to propel GENFIT forward in its mission to deliver transformative therapies. Prigent stated, "We are delighted to welcome Pejvack to GENFIT. His depth of knowledge will be invaluable as we enhance our pipeline."
GENFIT's Commitment to Liver Disease Research
GENFIT has established itself as a leader in addressing rare and life-threatening liver conditions, particularly Acute on-Chronic Liver Failure (ACLF) and its associated complications. The company is dedicated to developing innovative therapeutic solutions that target crucial pathophysiological pathways. Their research portfolio not only encompasses ACLF but also extends to serious illnesses such as cholangiocarcinoma, urea cycle disorders, and organic acidemia, ensuring continuous advancements in liver disease management.
Path to Innovative Approvals
In recent years, GENFIT achieved a substantial milestone with the accelerated approval of Iqirvo® (elafibranor) by various regulatory bodies for treating Primary Biliary Cholangitis. This illustrates GENFIT’s capacity to develop high-potential therapeutics from initial development through to commercialization, signifying a strong commitment to addressing unmet medical needs in liver diseases. Additionally, the company's diagnostic divisions have made strides, particularly with the NIS2+® franchise aimed at identifying Metabolic dysfunction-associated steatohepatitis, further solidifying its role in liver health diagnostics.
Corporate Structure and Future Directions
Operating from its headquarters in Lille, France, and with additional offices in Paris, Zurich, and Cambridge, MA, GENFIT continues to expand its influence within the biopharmaceutical landscape. The company is publicly listed on the Euronext regulated market in Paris under the ticker GNFT. With the recent investments including a notable acquisition of an 8% stake by Ipsen, GENFIT is well-positioned to further its research initiatives and expand its offerings to patients in need.
Frequently Asked Questions
Who is Dr. Pejvack Motlagh?
Dr. Pejvack Motlagh is the newly appointed Chief Medical Officer of GENFIT, bringing over 20 years of experience in drug development.
What role will Dr. Motlagh play at GENFIT?
He will oversee the clinical development strategy and lead key operational teams as part of GENFIT's Executive Committee.
What is GENFIT's main focus in the biopharmaceutical field?
GENFIT primarily focuses on rare and life-threatening liver diseases, especially Acute on-Chronic Liver Failure and its associated conditions.
What is Iqirvo®?
Iqirvo® (elafibranor) is a medication developed by GENFIT for treating Primary Biliary Cholangitis, which received accelerated approval from various regulatory agencies.
What other diseases does GENFIT target?
In addition to ACLF, GENFIT targets cholangiocarcinoma, urea cycle disorders, and organic acidemia, aiming to address significant medical needs across these areas.
